We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Benign Hematology

Journal Scan / Research · April 15, 2021

Vitamin K Antagonists vs Rivaroxaban in Hemodialysis Patients With Atrial Fibrillation

Journal of the American Society of Nephrology: JASN

 

Additional Info

Journal of the American Society of Nephrology: JASN
Safety and Efficacy of Vitamin K Antagonists Versus Rivaroxaban in Hemodialysis Patients With Atrial Fibrillation: A Multicenter Randomized Controlled Trial
J. Am. Soc. Nephrol. 2021 Mar 22;[EPub Ahead of Print], AS De Vriese, R Caluwé, H Van Der Meersch, K De Boeck, D De Bacquer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading